MetaCap

Eton Pharmaceuticals (ETON) vs Zymeworks (ZYME)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eton Pharmaceuticals (ETON) has outperformed Zymeworks (ZYME) over the past year, gaining 269.7% versus a gain of 8.8%. Over five years, ETON leads with a +1341.9% price change compared with +34.1% for ZYME. Zymeworks is the larger company by market cap ($1.81 billion vs $1.76 billion), about 1.0 times the size, while Eton Pharmaceuticals is growing revenue faster (+104.9% vs +38.9%).

On valuation, Eton Pharmaceuticals trades at a lower forward P/E (18.4x vs 55.0x for Zymeworks). Eton Pharmaceuticals converts more of its revenue into profit, with a net margin of -5.8% versus -76.6%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ETON+269.68%ZYME+8.83%
+332%+151%-29%
Nov 21, 20251 yearNov 20, 2026
ETON+1234.43%ZYME+31.95%
+1371%+613%-144%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ETON versus ZYME key metrics
MetricETONZYME
Share price$60.85$26.14
Market cap$1.76B$1.81B
1-day change-0.83%-2.68%
YTD return+259.85%-0.72%
1-year return+269.68%+8.83%
5-year return+1341.94%+34.05%
P/E ratio (TTM)39.5149.32
Forward P/E18.4154.95
EPS (TTM)$1.54$0.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$79.95M$105.97M
Revenue growth (YoY)+104.94%+38.87%
Net income (latest FY)$-4.60M$-81.13M
Gross margin53.46%—
Operating margin-1.06%-87.34%
Net margin-5.75%-76.56%
52-week high$70.64$31.97
52-week low$14.27$21.52
Distance from 52-week high-13.86%-18.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+32.70%+65.61%
Average volume570.79K1.09M
Shares outstanding28.84M68.70M
Employees44279
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ETON has outperformed ZYME by 260.9 percentage points over the past year.
  • Eton Pharmaceuticals is more profitable, keeping -5.8 cents of every revenue dollar as net income versus -76.6 cents for Zymeworks.
  • Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +38.87%).

About Eton Pharmaceuticals

ETON stock →

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About Zymeworks

ZYME stock →

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 279 employees

ETON vs ZYME FAQ

Which is bigger, Eton Pharmaceuticals or Zymeworks?

Zymeworks (ZYME) is larger, with a market capitalization of $1.81B compared with $1.76B for Eton Pharmaceuticals (ETON).

Which stock has performed better over the past year, ETON or ZYME?

ETON returned +269.68% over the past 12 months, compared with +8.83% for ZYME (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ETON or ZYME?

ETON has the lower trailing P/E at 39.5, versus 49.3 for ZYME. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Eton Pharmaceuticals and Zymeworks in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons